Sharon Worcester is an award-winning medical journalist for MDedge News. She has been with the company since 1996, first as the Southeast Bureau Chief (1996-2009) when the company was known as International Medical News Group, then as a freelance writer (2010-2015) before returning as a reporter in 2015. She previously worked as a daily newspaper reporter covering health and local government. Sharon currently reports primarily on oncology and hematology. She has a BA from Eckerd College and an MA in Mass Communication/Print Journalism from the University of Florida. Connect with her via LinkedIn and follow her on twitter @SW_MedReporter.
Article
CTCs help predict breast cancer outcomes in neoadjuvant setting
SAN ANTONIO – Circulating tumor cells are a useful prognostic biomarker in early breast cancer patients treated with neoadjuvant chemotherapy,...
Article
Neoadjuvant AI plus Ki67 info could deescalate adjuvant breast cancer treatment
Triage to chemotherapy based on a measurement of Ki67 proliferation after 2-4 weeks of neoadjuvant AI therapy for breast cancer is feasible and...
Article
Gene, risk signatures could predict PARP inhibitor response in breast cancer
SAN ANTONIO – PARPi 7, BRCAness, and MammaPrint high1/(ultra)high2 signatures could help predict response to combination therapy with the PARP...
Article
SLND after neoadjuvant chemo is feasible, but more study needed
SAN ANTONIO – Sentinel lymph node detection after neoadjuvant chemotherapy (NAC) is a safe and feasible strategy for preventing unnecessary...
Article
Cooling device reduces breast cancer–related alopecia during chemotherapy
SAN ANTONIO – About half of the women with stage 1 or 2 breast cancer who were treated using a scalp cooling device during chemotherapy retained...
Article
VIDEO: Abemaciclib reduces Ki67 expression in early HR+/HER2– breast cancer
SAN ANTONIO – Abemaciclib, both alone and in combination with anastrozole, significantly reduced Ki67 expression vs. anastrozole monotherapy after...
Article
VIDEO: No effect of BRCA status on overall outcomes in early-onset breast cancer
SAN ANTONIO – No difference in outcomes was seen among young BRCA gene mutation carriers and noncarriers with early stage invasive breast cancer...
Article
Next-generation sequencing highlights evolution of ER+ breast cancer
The “genomic landscape” of resistant estrogen receptor–positive metastatic breast cancer differs significantly from that of ER+ primary breast...
Article
VIDEO: Veliparib misses PFS endpoint, advances to phase III trial
SAN ANTONIO – Veliparib failed to significantly improve progression-free or overall survival when added to carboplatin and paclitaxel in patients...
Article
Low-dose IL-2 shows promise for refractory lupus
WASHINGTON
Article
Myeloablative HSCT bests IV CYC for systemic scleroderma
WASHINGTON – Myeloablative autologous hematopoietic stem cell transplantation showed long-term superiority over monthly intravenous...
Article
ADDRESS II study: Atacicept shows promise for SLE
WASHINGTON – The recombinant fusion protein atacicept, which targets B-cell stimulating factors BLyS and APRIL, had a favorable safety profile and...
Article
Idelalisib held unlikely to become frontline therapy for CLL
Safety issues with idelalisib, a first-in-class PI3K delta inhibitor, are an important concern in patients with chronic lymphocytic leukemia–...
Article
Ph-like ALL is highly prevalent in adults
Philadelphia chromosome–like acute lymphoblastic leukemia, which is a high-risk subtype of childhood ALL, accounts for more than 24% of ALL in...
Article
AURA-LV study: Rapid remission with voclosporin for lupus nephritis
WASHINGTON - The novel calcineurin inhibitor voclosporin, given in addition to mycophenolate mofetil and steroids, was associated with rapid and...